Amgen Inc. (0R0T.L)
- PR Newswire
AMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024
Amgen (NASDAQ:AMGN) today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE® (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD), which were accepted for presentation in the Clinical Trials Symposium at The American Thoracic Society (ATS) 2024 International Conference on Monday, May 20, from 9:15-11:15 a.m. PDT.
- PR Newswire
AMGEN PRESENTS NEW RESEARCH ON OTEZLA® (APREMILAST) AT AAD 2024
Amgen (NASDAQ:AMGN) today announced new, 52-week results from the Phase 3 SPROUT study examining the use of Otezla® (apremilast) in children and adolescents aged 6 to 17 years with moderate to severe plaque psoriasis. These data, along with findings from a Phase 3 late-breaking study on Otezla in palmoplantar pustulosis, will be presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting, March 8-12 in San Diego.
- PR Newswire
AMGEN ANNOUNCES 2024 SECOND QUARTER DIVIDEND
Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.25 per share dividend for the second quarter of 2024. The dividend will be paid on June 7, 2024, to all stockholders of record as of the close of business on May 17, 2024.
